Xavier Gonzàlez Farré

Associate professor

Universitat Internacional de Catalunya

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Xavier Gonzàlez Farré is an Associate Professor at the Universitat Internacional de Catalunya, Spain. His research primarily focuses on innovative treatments for breast cancer, including HER2-positive and hormone receptor-positive subtypes. His recent publications explore various therapeutic strategies, including the use of palbociclib, trastuzumab, and oncolytic viruses in clinical settings.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Collaborators (5)

Manel Juan

Head of Immunology service/department

Hospital Clínic de Barcelona

SPAIN

View details

SONIA PERNAS SIMON

Associate Professor

University of Barcelona

SPAIN

View details

Ana Arance

University of Barcelona

SPAIN

View details

Jordi Canes

Scientific Manager Head

SPAIN

View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Xavier Gonzàlez Farré

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy

Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of <i>PD1</i> mRNA

Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.

Collaborators (5)

Manel Juan

SONIA PERNAS SIMON

Ana Arance

Jordi Canes

ENRIQUETA FELIP

Make your next move.